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Background: An increased incidence of venous thromboembolism (VTE) is associated with anti-vascular endothelial
growth factor (VEGF) treatment in cancer. However, the mechanism underlying this effect remains elusive. In this
study, we examined the effect of bevacizumab, a humanized monoclonal antibody against VEGF-A, on VTE in a
murine xenograft A549 cell tumor model.
Methods: Inferior vena cava stenosis model and FeCl3-induced saphenous vein thrombosis model were performed
in a mouse xenograft models of human lung adenocarcinoma.
Results: We found that treatment with bevacizumab significantly increased the thrombotic response to
inferior vena cava obstruction and femoral vein injury. Plasminogen activator inhibitor (PAI-1) expression in
tumors, plasma, and thrombi was significantly increased by bevacizumab. However, bevacizumab did not
enhance VTE in PAI-1-deficient mice, suggesting that PAI-1 is a major mediator of bevacizumab’s
prothrombotic effect. VEGF inhibited expression of PAI-1 by A549 cells, and this effect was neutralized by
bevacizumab, suggesting that bevacizumab increases PAI-1 expression in vivo by blocking the inhibitory effect
of VEGF on PAI-1 expression by tumor cells. Pharmacological inhibition of PAI-1 with PAI-039 blocked
bevacizumab-induced venous thrombosis.
Conclusion: Collectively, these findings indicate that PAI-1 plays a role in VTE associated with antiangiogenic
therapy and the inhibition of PAI-1 shows efficacy as a therapeutic strategy for the prevention of
bevacizumab-associated VTE.
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Numerous clinical studies have suggested that the inci-
dence of thromboembolic complications is further in-
creased in cancer patients treated with antiangiogenic
agents [1]. Experiments involving have shown that treat-
ment via the inhibition of VEGF signaling significantly
inhibits the resolution of venous thrombi, which could* Correspondence: wuji@missouri.edu
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thrombus extension [2–4].
Bevacizumab, a recombinant humanized monoclonal
neutralizing antibody against VEGF that has shown ben-
efits in the treatment of many types of malignancy, in-
cluding colorectal cancer, non-small cell lung cancer
(NSCLC), renal cell carcinoma, and breast cancer, has
been associated with an increased risk of serious venous
thromboembolic events [5]. However, no study has yet
assessed the effect of bevacizumab on the processes that
govern the development of venous thrombosis. Plasmino-
gen activator inhibitor-1 (PAI-1), the primary endogenousicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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urinary-type plasminogen activator (uPA), has increasingly
been associated with tumor growth, invasion, and metas-
tasis. Increased PAI-1 expression by tumors is correlated
with a poor prognosis [6, 7]. An elevated PAI-1 level may
contribute to the development of thrombosis and has
been associated with VTE [8, 9]. The objective of the
present study was to determine the effect of bevacizumab
on venous thrombosis in a xenograft mouse model of hu-
man lung tumors. Using pharmacological and genetic
models of PAI-1 modulation, we examined role of PAI-1
as a mediator of bevacizumab’s prothrombotic effect, and
tested whether the inhibition of PAI-1 can block
bevacizumab-induced venous thrombosis.
Results and discussion
We injected A549 cells in nude mice. After 7 weeks of
tumor growth we studied venous thrombosis in tumor-
bearing mice and age-matched control nude mice not
bearing tumor cells. Weight of thrombi induced by infer-
ior vena cava (IVC) partial obstruction was significantly
greater in tumor-bearing mice than non-tumor-bearing
controls (7.8 ± 1.5 mg vs. 5.6 ± 0.6 mg, respectively; n = 6/
group; p < 0.01). Similarly, venous thrombosis in responseFig. 1 Bevacizumab promotes venous thrombosis. a. IVC stenosis was i
ligation, mice were euthanized and the weight of the thrombus was d
thrombi retrieved from mice treated with bevacizumab (Beva) or vehic
vein thrombosis was induced using 10 % FeCl3 in control (n = 6) and
and are shown as the mean ± SEM. *P < 0.05 vs. the vehicle group. c. T
Western blotting to detect VEGF-A, PAI-1, and β-actin. Representative b
shown. *P < 0.05 vs. control. d. Plasma PAI-1 antigen was measured (nto saphenous vein injury was significantly accelerated
in mice bearing A549 tumors vs. negative controls
(684 ± 65 sec vs. 828 ± 51 sec, respectively; n = 6/group;
p < 0.05). These findings confirmed that our tumor
model induced a prothrombotic state. In a parallel ex-
periment, we inoculated nude mice with A549 cells.
When tumors reached ~500 mm3 in size, bevacizumab
was administered by weekly injection for up to 7 weeks,
after which venous thrombosis induced by IVC stenosis
was compared to the non-bevacizumab treated tumor-
bearing mice described above. Bevacizumab treatment re-
sulted in larger thrombi than those found in vehicle-treated
mice (11.2 ± 1.6 mg vs. 7.8 ± 1.5 mg, respectively; n = 6/
group; p < 0.05; Fig. 1a). In addition, bevacizumab-treated
mice showed significantly shortened saphenous vein occlu-
sion times following ferric chloride injury compared with
vehicle-treated mice (411 ± 47 seconds vs. 684 ± 65 seconds,
respectively; p < 0.05; Fig. 1b). These results indicated that
treatment with bevacizumab promoted venous thrombosis
in tumor-bearing mice.
To examine the potential role of PAI-1 in mediating
the prothrombotic effect of bevacizumab, Western blot
analysis using anti-human PAI-1 antibody showed that
bevacizumab significantly increased tumor PAI-1 proteinnduced in tumor-bearing mice (n = 6/group). Three hours after
etermined. Representative whole thrombi and cross-sections of
le control are shown. *P < 0.05 vs. vehicle control. b. Saphenous
A549 tumor-bearing mice (n = 6). Occlusion times were measured
umors were excised and lysates were prepared and subjected to
lots and densitometric analyses of 3 independent experiments are
= 6/group); *P < 0.05 vs. the vehicle group. Beva: bevacizumab
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plasma concentration of tumor-derived PAI-1, which
could be determined given the human origin of A549
cells and the species-specific nature of the ELISA we
employed (Fig. 1d), as non-tumor-bearing mice showed
no human PAI-1 in plasma. In addition, PAI-1 gene ex-
pression in the cellular component of thrombi induced
by venous stasis, assessed by real-time RT-PCR, was sig-
nificantly greater in bevacizumab-treated mice vs.
vehicle-treated controls (Fig. 2a). At present it is difficult
to state which cell type is a major target for bevacizumab
to produce PAI-1 mRNA into thrombi. Potentially im-
portant source of PAI-1, besides the endothelial cells,
platelets, and leukcytes, circulating tumor cells may play
a role in the association between cancer and thrombosis.
To assess the causal role of PAI-1 in bevacizumab-
enhanced thrombosis, we administered bevacizumab or
vehicle control to wild-type and Pai1−/− C57Bl/6 mice.
In WT mice, bevacizumab promoted venous thrombosis
(Fig. 2b), indicating that bevacizumab exerts a host-Fig. 2 Bevacizumab promotes venous thrombosis in a PAI-1-dependent
bevacizumab and vehicle groups was determined via real-time RT-PCR.
vehicle group. b. IVC stenosis was induced in WT and Pai-1−/− mice (n
the weight of the thrombus was determined. *P < 0.05 vs. the vehicle
#P < 0.05 vs. the bevacizumab group in WT mice, and #P = 0.74 vs. the
thrombosis was induced using 10 % FeCl3 in WT and Pai-1−/− mice (n
mean ± SEM. *P < 0.05 vs. the vehicle group in WT mice; **P < 0.05 vs.
in WT mice. d. A549 cells were cultured for 24 hrs in the presence and
indicated. Cell lysates were prepared and subjected to Western blotting
analyses of 3 independent experiments are shown. *P < 0.05 vs. controdependent, prothrombotic effect, even in the absence of
tumor cells. Similarly, venous thrombosis in response to
saphenous vein injury was significantly accelerated in
mice treated by bevacizumab vs. negative controls in
WT mice (428 ± 45 sec vs. 276 ± 11 sec, respectively; n =
4/group; p < 0.05) (Fig. 2c). However, the prothrombotic
effect of bevacizumab was lost in PAI-1-deficient mice,
suggesting that PAI-1 is a major mediator of bevacizu-
mab’s prothrombotic effect. Additional experiments, such
as thromboelastogram or multiplate functional test, will
be necessary to further clarify the potential importance in
future studies.
To study potential mechanisms by which bevacizumab
might increase PAI-1 expression, we examined the effect
of VEGF on PAI-1 expression by A549 cells grown in
culture. VEGF inhibited PAI-1 expression by tumor cells
(Fig. 2d). Bevacizumab promoted PAI-1 expression in
VEGF-treated A549 cells, consistent with bevacizumab’s
VEGF-neutralizing function. Western blot analysis using
anti-human VEGF antibody showed that abundantmanner. a. The intrathrombotic gene expression of PAI-1 in the
All values represent mean ± SEM (n = 6/group). *P < 0.01 vs. the
= 6/group). Ten days after ligation, all mice were euthanized, and
group in WT mice; **P < 0.05 vs. the vehicle group in WT mice;
vehicle group in Pai-1−/− mice (n = 6/group). c. Saphenous vein
= 6/group). Occlusion times were measured and are shown as the
the vehicle group in WT mice; #P < 0.05 vs. the bevacizumab group
absence of VEGF (50 ng/mL) and bevacizumab (250 μg/mL), as
to detect PAI-1and β-actin. Representative blot and densitometric
l (i.e. no VEGF or Beva)
Fig. 3 Pharmacological inhibition of PAI-1 blocks the prothrombotic
effect of bevacizumab. a. IVC stenosis was induced in tumor-bearing
mice. The mean weight of the thrombus was determined. *P < 0.05
vs. the vehicle group; **P < 0.05 vs. the beva group; #P > 0.05 vs.
beva + PAI-039 group (n = 6/group). b. Mean occlusion times were
measured in a saphenous vein thrombosis model and are shown as
the mean ± SEM. *P < 0.01 vs. the vehicle group; **P < 0.05 vs. the
beva group; #P > 0.05 vs. beva + PAI-039 group (n = 6/group).
Beva: bevacizumab
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bevacizumab potently decreased VEGF protein concentra-
tion in tumors (Fig. 1c), providing an additional mechan-
ism by which bevacizumab increases PAI-1 expression by
tumor cells. As a whole, these data suggest that bevacizu-
mab increases PAI-1 expression in vivo in tumor-bearing
mice by blocking the inhibitory effect of VEGF on PAI-1
expression by tumor cells. It should also be noted that al-
though bevacizumab has been described as binding specif-
ically to human VEGF-A, a direct weak interaction with
murine VEGF was found to be sufficient to exert this ef-
fect [10, 11]. Bevacizumab exhibited to cross-reactive with
other species and has been shown to inhibit the growth of
a variety of human tumor cell lines in nude mice [12, 13].
Previous studies revealed that bevacizumab does interact
with mouse VEGF using three independent molecular bio-
logical assays (Western blot analysis, ELISA, and BIAcore
assay), and the interaction was sufficient to induce potent
inhibitory effects in murine models of corneal hemangio-
genesis, lymphangiogenesis, and neovascularization and in
a murine subcutaneous lung tumor model [14].
Next, we studied whether PAI-039, a specific, orally
available pharmacological inhibitor of PAI-1 [15, 16],
can inhibit the prothrombotic effect of bevacizumab. In
tumor bearing mice, PAI-039 significantly reduced the
weight of thrombi induced by IVC partial obstruction
(Fig. 3a) and delayed the time to formation of occlusive
thrombosis after saphenous vein injury compared to
vehicle-treated controls (896 ± 67 sec vs. 711 ± 93 sec
respectively, p < 0.05; Fig. 3b). Furthermore, bevacizu-
mab had no significant prothrombotic effect in the pres-
ence of PAI-039, further suggesting that PAI-1 is a
dominant mediator of bevacizumab’s prothrombotic ef-
fect. PAI-039 had no significant effect on tumor volume
(Fig. 4a-c), suggesting that the antithrombotic effect of
PAI-039 could not be explained by inhibition of tumor cell
growth [17].Conclusions
Taken together, our data show that bevacizumab pro-
motes venous thrombosis through the induction of PAI-
1 in a mouse xenograft model of human lung carcinoma,
and that pharmacological inhibition of PAI-1 may repre-
sent a useful strategy for the prevention of venous
thrombosis associated with bevacizumab treatment.Materials and methods
Cell culture
Human A549 lung adenocarcinoma cell line stably trans-
fected with luciferase (A549luc) was purchased from Cali-
per Life sciences Corp. Cells were cultured in DMEM
media supplemented with 10 % fetal calf serum (FCS), 100
U/ml penicillin and 100 U/ml streptomycin.Animals
Male BALB/c nude mouse mice aged 4 weeks were
used for human tumor xenograft model (supplied by
the Chongqing Medical University Animal Center,
Chongqing, China). C57BL/6 J mice were from Jackson
Labs. C57BL/6 J-congenic PAI-1-deficient (Pai1−/−) mice
were a gift from Dr. Peter Carmeliet, University of Leuven,
Leuven, Belgium [18]. All protocols for animal use were
reviewed and approved by the Animal Care Committee of
Sichuan Medical University in accordance with Institu-
tional Animal Care and Use Committee guidelines.
Tumor model
Male nude mice were anesthetized with ketamine/xylazine,
and 1×106 A549 cells were injected in the flank. Tumor
volumes were measured every 3 days using Vernier calipers,
and volumes were calculated using a standard formula
Fig. 4 Tumor growth inhibition by bevacizumab in orthotopic A549 xenografts. a. A549 tumor growth curves of nude mice receiving
bevacizumab (Beva; 200 μg/mouse; once weekly), PAI-039 (2 mg/kg/day), both, or vehicle control (n = 6/group). Arrow denotes first
bevacizumab injection. Tumor sizes of Beva and Beva + PAI-039 groups were significantly less than those of vehicle group (P < 0.05) at
24 days and all subsequent time points, whereas differences between PAI-039 and vehicle groups were not statistically significant at any
time point. b. Representative images of tumors retrieved at completion of treatment protocol. c. Bioluminescent imaging of A549-luc
tumors after completion of treatment protocol. Note smaller tumor sizes in bevacizumab-treated mice
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500 mm3, mice were given bevacizumab (200 μg, adminis-
tered by intraperitoneal injection) or vehicle control, after
which the same dose was administered every 7 days for
50 days [19]. After completing treatment protocols, mice
received D-luciferin (1.5 mg), administered by intraperito-
neal injection. 3 hours later mice were euthanized and tu-
mors were imaged by bioluminescence method using an
In-Vivo Imaging System (Bruker).
Thrombosis models
The IVC stenosis model, which reduces lumen size
by approximately 90 %, was performed as described
previously [20, 21], Three hours or 10 days after cre-
ation of the stenosis, mice were euthanized. Thrombi
were removed from the IVC and weighed. The
FeCl3-induced saphenous vein thrombosis model was
performed as described previously [22]. Blood flow
was recorded with a color laser Doppler image scan-
ner (Moor LDI, Moor Instruments Ltd) as previously
described. Flow was monitored continuously from
the onset of injury until stable occlusion occurred
(defined as no flow for ≥ 10 minutes) or for 60 mi-
nutes if occlusion did not occur. Occlusion time wasdefined as the interval between the initiation of vas-
cular injury and the onset of stable occlusion.
Administration of PAI-039
PAI-039 is an orally available, specific inhibitor of active
PAI-1 [15]. When the average A549 tumor size reached ~
500 mm3, mice were treated with PAI-039 (2 mg/kg/day;
dissolved in vehicle consisting of sterile water containing
0.5 % methylcellulose and 2 % Tween 80), or vehicle con-
trol, administered for 50 consecutive days by twice daily
oral gavage.
Blood collection and plasma preparation
At time of euthanasia, whole blood was collected from
the IVC into sodium citrate anticoagulant. Plasma was
prepared by centrifugation at 4000 g for 15 minutes,
followed by a clearance centrifugation of 13000 g for
2 minutes. Plasma was divided into 50 μL aliquots and
frozen at −80 °C.
Quantitative real-time PCR
Total RNA was extracted from IVC thrombus using TRIzol
(invitrogen). RNA was pretreated with deoxyribonuclease I
(Invitrogen Life Technologies), and SuperScript (Invitrogen
Chen et al. Molecular Cancer  (2015) 14:140 Page 6 of 7Life Technologies) was used to synthesize cDNA according
to the manufacturer’s recommended conditions. Each sam-
ple was analyzed in duplicate with ribosomal 18S mRNA
used as controls. After amplification, the relative differences
in amounts of RNA were calculated based on the 2−Δ ΔCT
method. The oligonucleotide sequences of PCR primers
were: (1) mouse PAI-1 (GGACACCCTCAGCATGTTCA,
TCTGATGAGTTCAGCATCCAAGAT); (2) 18S (CCTGG
ATACCGCAGCTAGGA, GCGGCGCAATACGAATGCC
CC). Human VEGF (CCAGGCCCTCGTCATTG, AAG-
GAGGAGGGCAGAATCAT); mouse VEGF (CTCCAGG
GCTTCATCGTTA, CAGAAGGAGAGCAGAAGTCC);
human B-actin (GGAGGAGCTGGAAGCAGCC, GCTGT
GCTACGTCGCCCTG); mouse b-actin (GGAGGAAGAG
GATGCGGCA, GAAGCTGTGCTATGTTGCTCTA).
Immunoblotting
Tumor tissues were homogenized in RIPA buffer
(Sigma). Total protein concentration of the homogenates
was measured with the BCA reagent. Equal amounts of
protein were subjected to SDS-PAGE and transferred to
polyvinylidene difluoride membranes by electroblotting.
After blocking, the membranes were incubated with
antibodies directed against human VEGF-A, human
PAI-1, and β-actin.
ELISA
Thrombi were retrieved from IVC 10 days after IVC
ligation and homogenized in 0.3 mL of PBS (pH 7.2)
containing Complete Protease Inhibitor Mixture (Roche
Diagnostics). Homogenates were centrifuged at 12,000 g
for 15 minutes. PAI-1 antigen in supernatants was mea-
sured using a mouse total PAI-1 antigen assay ELISA kit
(Molecular Innovations).
Statistical analysis
Data are presented as mean ± standard error of the
mean. Experimental groups were compared by the two-
tailed Student’s t-test or one-way analysis of variance
(ANOVA).
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